Lilly joins the push for non-opioid painkillers

By Maggie Lynch

- Last updated on GMT

(Image: Getty/dragana991)
(Image: Getty/dragana991)

Related tags Eli lilly Eli lilly and company Opioid Opioid epidemic Pain

Eli Lilly acquires exclusive worldwide rights for non-opioid treatment for chronic pain from Centrexion through a licensing agreement.

Centrexion, a late clinical-stage biopharmaceutical company specializing in non-addictive therapies for pain, licensed its non-opioid treatment for chronic pain, CNTX-0290, to Eli Lilly.

The treatment is a small molecule somatostatin receptor type 4 agonist, which Eli Lilly acquired under a potential $997.5m (€891m) agreement.

Per the license, Lilly will pay Centrexion $47.5m upfront, and the latter will be eligible for up to $575m in development and regulatory milestones, and $375m in potential sales milestones and royalties. Lilly and Centrexion may also work together to co-promote CNTX-0290 in the US – should the development of the drug candidate prove successful.

The drug is currently in Phase I clinical trials as a non-opioid treatment for chronic pain conditions.

A push for non-opioids

As public health officials cite that opioid usage in the US is at an epidemic level, and the National Institute on Drug Abuse​ stated that roughly 21% to 29% of individuals prescribed opioids misuse them, there has been a push for the development of non-opioid options for the treatment of pain.

Purdue Pharma recently entered a partnership with Alivio ​to develop a non-opioid painkiller in January 2019. The OxyContin (oxycodone HCI) producer paid Alivio Therapeutics $14.75m upfront to advance the company’s lead drug candidate, ALV-107.

Aside from the push for non-opioid painkillers, the US Department of Defense (DOD) granted Phoenix PharmaLabs $2.7m to develop a non-addictive opioid. The DOD granted the pharmaceutical company the financing to develop its candidate PPL-103 that stimulates three opioid receptors without creating the euphoric feeling associated with opioids.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us